tools
Recursion OS
Piattaforma di IA per la scoperta e lo sviluppo di farmaci che collega esperimenti biologici, modelli computazionali, progettazione chimica e sviluppo clinico.
In inglese
Recursion OS is Recursion’s proprietary platform for drug discovery and development. It combines automated wet-lab experiments, computational analysis, machine learning models, chemistry design, and clinical development workflows in a feedback loop.
Recursion and its pharmaceutical partners use it to identify biological targets, design molecules, validate candidates, and support clinical trial planning. The site does not show public self-serve plans or pricing, and the platform is not presented as a general-purpose consumer AI tool.
Features
- Maps disease biology with high-dimensional cellular experiments
- Generates digital representations of biological and chemical experiments
- Uses machine learning and purpose-built large language models
- Supports target identification and biological insight generation
- Designs potential medicines with generative de novo chemistry
- Connects automated wet labs with computational analysis
- Supports clinical development and trial enrollment workflows
- Includes Recursion OS 2.0 workflows for biology, design, and clinical development
Use cases
- Identify disease-relevant biological targets
- Design and prioritize potential drug compounds
- Run integrated design-make-test-learn cycles
- Validate computational predictions in automated laboratories
- Select patients and support clinical trial execution
Pros
Cons
Latest updates
- Unlocking the First Neuroscience Target for the Recursion and Genentech Collaboration
Unlocking a neuroscience target for the Recursion and Genentech collaboration.
- New Data’s Not Enough. How Recursion Is Integrating Data Layers to Advance End-to-End Drug Discovery
Integrating data layers to advance end-to-end drug discovery.
- Since Its Inception, Recursion has Been Building the Foundation for the First Virtual Cell
Building the foundation for a virtual cell.
- How a First-of-its-Kind “Microglia Map” from Recursion and Roche and Genentech Could Unlock New Treatments for Neurodegenerative Diseases
A microglia map from Recursion and Roche and Genentech could unlock treatments.
- The Quest for Better Protein-Ligand Interaction Modeling – Improving ML Methods Offer Promise for AI Drug Discovery
Improving ML methods for protein-ligand interaction modeling.
Pricing
- Prices checked
- 2026-10-25